BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38498975)

  • 21. A Phase II Study of Avelumab Monotherapy in Patients with Mismatch Repair-Deficient/Microsatellite Instability-High or POLE-Mutated Metastatic or Unresectable Colorectal Cancer.
    Kim JH; Kim SY; Baek JY; Cha YJ; Ahn JB; Kim HS; Lee KW; Kim JW; Kim TY; Chang WJ; Park JO; Kim J; Kim JE; Hong YS; Kim YH; Kim TW
    Cancer Res Treat; 2020 Oct; 52(4):1135-1144. PubMed ID: 32340084
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.
    Abida W; Cheng ML; Armenia J; Middha S; Autio KA; Vargas HA; Rathkopf D; Morris MJ; Danila DC; Slovin SF; Carbone E; Barnett ES; Hullings M; Hechtman JF; Zehir A; Shia J; Jonsson P; Stadler ZK; Srinivasan P; Laudone VP; Reuter V; Wolchok JD; Socci ND; Taylor BS; Berger MF; Kantoff PW; Sawyers CL; Schultz N; Solit DB; Gopalan A; Scher HI
    JAMA Oncol; 2019 Apr; 5(4):471-478. PubMed ID: 30589920
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of preoperative immunotherapy in patients with mismatch repair-deficient or microsatellite instability-high gastrointestinal malignancies.
    Li YJ; Liu XZ; Yao YF; Chen N; Li ZW; Zhang XY; Lin XF; Wu AW
    World J Gastrointest Surg; 2023 Feb; 15(2):222-233. PubMed ID: 36896306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nonoperative Management of dMMR/MSI-H Colorectal Cancer following Neoadjuvant Immunotherapy: A Narrative Review.
    Xiao B; Yu J; Ding PR
    Clin Colon Rectal Surg; 2023 Nov; 36(6):378-384. PubMed ID: 37795463
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PD-1 blockade in neoadjuvant setting of DNA mismatch repair-deficient/microsatellite instability-high colorectal cancer.
    Liu DX; Li DD; He W; Ke CF; Jiang W; Tang JH; Kong LH; Li Y; Sui QQ; Xiao BY; Li WR; Hong ZG; Xu RH; Pan ZZ; Zhang XS; Ding PR
    Oncoimmunology; 2020; 9(1):1711650. PubMed ID: 32042474
    [No Abstract]   [Full Text] [Related]  

  • 26. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial.
    Hu H; Kang L; Zhang J; Wu Z; Wang H; Huang M; Lan P; Wu X; Wang C; Cao W; Hu J; Huang Y; Huang L; Wang H; Shi L; Cai Y; Shen C; Ling J; Xie X; Cai Y; He X; Dou R; Zhou J; Ma T; Zhang X; Luo S; Deng W; Ling L; Liu H; Deng Y
    Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):38-48. PubMed ID: 34688374
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors.
    Li J; Deng Y; Zhang W; Zhou AP; Guo W; Yang J; Yuan Y; Zhu L; Qin S; Xiang S; Lu H; Gong J; Xu T; Liu D; Shen L
    J Hematol Oncol; 2021 Jun; 14(1):95. PubMed ID: 34154614
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.
    Overman MJ; McDermott R; Leach JL; Lonardi S; Lenz HJ; Morse MA; Desai J; Hill A; Axelson M; Moss RA; Goldberg MV; Cao ZA; Ledeine JM; Maglinte GA; Kopetz S; André T
    Lancet Oncol; 2017 Sep; 18(9):1182-1191. PubMed ID: 28734759
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathological complete response after neoadjuvant immunotherapy combined with chemotherapy in pediatric rectal carcinoma: A case report.
    Cao X; Luo J; Zhao B; Fu H; Kang W
    Front Immunol; 2022; 13():1036181. PubMed ID: 36544760
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunotherapy in MSI/dMMR tumors in the perioperative setting: The IMHOTEP trial.
    Coutzac C; Bibeau F; Ben Abdelghani M; Aparicio T; Cohen R; Coquan E; Dubreuil O; Evesque L; Ghiringhelli F; Kim S; Lesourd S; Neuzillet C; Phelip JM; Piessen G; Rochigneux P; Samalin E; Soularue E; Touchefeu Y; Tougeron D; Zaanan A; de la Fouchardière C
    Dig Liver Dis; 2022 Oct; 54(10):1335-1341. PubMed ID: 35907691
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
    Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
    Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden.
    Quintanilha JCF; Graf RP; Fisher VA; Oxnard GR; Ellis H; Panarelli N; Lin DI; Li G; Huang RSP; Ross JS; Myer PA; Klempner SJ
    JAMA Netw Open; 2023 Jan; 6(1):e2252244. PubMed ID: 36689222
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-world study on microsatellite instability and mismatch repair deficiency testing patterns among patients with metastatic colorectal cancer in Spain.
    Garcia-Carbonero R; González Astorga B; Vidal Tocino R; Contreras Toledo D; Pericay C; Fernández Montes A; Falcó E; González Cordero M; Reina Zoilo JJ; Alonso V; Rodríguez Salas N; Gil-Raga M; Santos C; Páez D; Anton-Pascual B; Aguilar F; Morales P
    Clin Transl Oncol; 2024 Apr; 26(4):864-871. PubMed ID: 37651021
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer.
    Morse MA; Overman MJ; Hartman L; Khoukaz T; Brutcher E; Lenz HJ; Atasoy A; Shangguan T; Zhao H; El-Rayes B
    Oncologist; 2019 Nov; 24(11):1453-1461. PubMed ID: 31147488
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neoadjuvant Immune Checkpoint Inhibition Improves Organ Preservation in T4bM0 Colorectal Cancer With Mismatch Repair Deficiency: A Retrospective Observational Study.
    Han K; Tang JH; Liao LE; Jiang W; Sui QQ; Xiao BY; Li WR; Hong ZG; Li Y; Kong LH; Li DD; Zhang XS; Pan ZZ; Steele SR; Ding PR
    Dis Colon Rectum; 2023 Oct; 66(10):e996-e1005. PubMed ID: 35485833
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment for mismatch-repair-deficient (dMMR) or microsatellite-instability-high (MSI-H) advanced or metastatic colorectal cancer from the perspective of the Chinese health-care system.
    Zhu C; Han G; Wu B
    BMC Health Serv Res; 2023 Oct; 23(1):1083. PubMed ID: 37821934
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalent Pseudoprogression and Pseudoresidue in Patients With Rectal Cancer Treated With Neoadjuvant Immune Checkpoint Inhibitors.
    Xie Y; Lin J; Zhang N; Wang X; Wang P; Peng S; Li J; Wu Y; Huang Y; Zhuang Z; Shen D; Zhu M; Liu X; Liu G; Meng X; Huang M; Yu H; Luo Y
    J Natl Compr Canc Netw; 2023 Feb; 21(2):133-142.e3. PubMed ID: 36791752
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer.
    Colle R; Radzik A; Cohen R; Pellat A; Lopez-Tabada D; Cachanado M; Duval A; Svrcek M; Menu Y; André T
    Eur J Cancer; 2021 Feb; 144():9-16. PubMed ID: 33316636
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair.
    Ratovomanana T; Cohen R; Svrcek M; Renaud F; Cervera P; Siret A; Letourneur Q; Buhard O; Bourgoin P; Guillerm E; Dorard C; Nicolle R; Ayadi M; Touat M; Bielle F; Sanson M; Le Rouzic P; Buisine MP; Piessen G; Collura A; Fléjou JF; de Reyniès A; Coulet F; Ghiringhelli F; André T; Jonchère V; Duval A
    Gastroenterology; 2021 Sep; 161(3):814-826.e7. PubMed ID: 33992635
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The efficacy and safety of neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced rectal cancer patients: a systematic review.
    Yang L; Cui X; Wu F; Chi Z; Xiao L; Wang X; Liang Z; Li X; Yu Q; Lin X; Gao C
    Front Immunol; 2024; 15():1392499. PubMed ID: 38846948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.